Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Drug Import Bill Would Require Notice Of Manufacturing Changes

Executive Summary

Drug manufacturers would be required to notify FDA of any manufacturing changes that might serve to circumvent reimportation under bipartisan legislation introduced by Sens. Byron Dorgan (D-N.D.) and Edward Kennedy (D-Mass.) April 21

You may also be interested in...



Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight

A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight

Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight

A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight

Rx Import Debate Launches In Senate With Introduction Of Four Bills

The drug importation debate was launched in the Senate the week of Jan. 24 with the introduction of several bills

Related Content

UsernamePublicRestriction

Register

PS043838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel